Bemcentinib is under clinical development by BerGenBio and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bemcentinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bemcentinib overview

Bemcentinib (BGB-324, R-428) is under development for the treatment of inflammatory breast cancer, idiopathic pulmonary fibrosis, metastatic melanoma, relapsed/refractory acute myeloid leukaemia, myelodysplastic syndrome, STK11 mutated metastatic non-squamous non-small cell lung cancer including lung adenocarcinoma, malignant mesothelioma, glioblastoma, nonalcoholic steatohepatitis (NASH), bladder cancer, renal cell carcinoma, acute respiratory distress syndrome and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV), influenza and rhinovirus infections. It is administered through oral route and acts by targeting Axl kinase. The drug candidate is a first-in-class selective AXL kinase inhibitor. The drug candidate is based on CellSelect Technology. It was also under development for chronic myelocytic leukemia, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma and liver fibrosis, recurrent glioblastoma.

BerGenBio overview

BerGenBio focuses on the development of transformative drugs built on AXL receptor tyrosine kinase (AXL) inhibitors for the treatment of therapy-resistant cancers. Its pipeline products include Bemcentinib (BGB324), Tilvestamab BGB149 and BGB601 (ADCT-601). Bemcentinib (BGB324) is an orally bioavailable and AXL inhibitor, which is used for the treatment of advanced non-small-cell lung cancer (NSCLC), high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and Covid – 19. Tilvestamab BGB149 is a functional blocking anti-AXL monoclonal antibody, which prevents AXL-mediated cell signaling in cancer cell lines, illustrates anti-tumor efficacy and decreases cell migration and invasion. BerGenBio is headquartered in Bergen, Norway.

For a complete picture of Bemcentinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.